Skip to content

Multi-Component Technology Intervention for Minority Emerging Adults With Asthma

Multi-Component Technology Intervention for Minority Emerging Adults With Asthma

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01714141
Enrollment
48
Registered
2012-10-25
Start date
2011-12-31
Completion date
2015-09-30
Last updated
2016-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Poor Medication Adherence

Keywords

Technology based intervention, Emerging adults, African Americans, Asthma, Controller medications, Motivational intervention

Brief summary

This pilot study's main goal is to develop and preliminarily test a technology-based intervention to improve asthma medication adherence in urban African American emerging adults (ages 18-29). It is hypothesized that youth randomized to MCTI for adherence will show improvements in motivation to adhere to asthma medications and self-reported adherence compared to the comparison condition at 1- and 3- month follow up.

Detailed description

This study collected pilot data with a sample of 48 African American emerging adults with asthma with suboptimal medication adherence. Half of the sample were randomized to receive a multi-component technology-based intervention (MCTI) targeting adherence to daily controller medication. The MCTI consisted of two components: 1) 2 sessions of computer-delivered motivational interviewing targeting medication adherence, and 2) individualized text messaging focused on medication adherence between the sessions. Text messages were individualized based on Ecological Momentary Assessment (EMA). The remaining half of participants completed a series of computer-delivered asthma education modules matched for length, location, and method of delivery of the intervention session. Control participants also received text messages between intervention sessions. Message content was the same for all control participants and contain general facts about asthma (not tailored).

Interventions

BEHAVIORALMulti-component, technology based intervention

Motivational sessions were adapted from work done with young adults with HIV (MESA).

BEHAVIORALAsthma education active control

Sponsors

Wayne State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 29 Years
Healthy volunteers
No

Inclusion criteria

African American Live in the Detroit Area, approximately 30 miles from the Hutzel Building Ages 18-29 Have moderate to severe persistent asthma. Persistent asthma is defined according to the 2007 NHLBI guidelines. The level of symptoms, as defined by any of the following in the last 4 weeks: Use of any asthma medication more than 2 times a week Daytime asthma symptoms such as wheezing, tightness of chest, problems coughing more than 2 times a week, or waking up at night because of asthma more than 2 times a month Participant is prescribed a daily asthma controller medication, even if they do not take it. Participant must report poor adherence to daily controller medications during eligibility screening (brief interview). Poor adherence is defined as not taking medications as prescribed less than 4 days per week in any of the 4 weeks prior to enrollment OR as a proxy of poor adherence as self-report of \<80% medication adherence in the past 30 days, self-report of emergency room visit/hospitalization for asthma in the past 6 months, or a poor score on the Asthma Control Test. Participant must be able to complete questionnaires in English Participant must own or have access to a cellular phone for the duration of the study No exclusions will be made due to co-morbid mental health problems (i.e. ADHD, depression) except thought disorders (i.e. schizophrenia, autism), suicidality or mental retardation.

Exclusion criteria

Individuals with other chronic health conditions requiring ongoing medical intervention ( e.g., HIV, Type II Diabetes) will be excluded. These chronic diseases include: Glaucoma, bi-polarism, segmented glomerular nephritis, cystic fibrosis, spondyloarthropathy, congenital heart disease, sickle cell No pregnant women will be included in this study.

Design outcomes

Primary

MeasureTime frameDescription
Change in medication adherencebaseline, 1 month, 3 monthSelf-reported adherence to asthma controller medication(s) through questionnaire report and, at baseline and 3 months, 7 days of momentary (real time) sampling of adherence behavior via SMS text messaging.
Change in motivation for medication adherencebaseline, 1 month, 3 monthSelf-report of motivation to take asthma controller medications as prescribed.

Secondary

MeasureTime frameDescription
Change in asthma medication importancebaseline, 1 month, 3 monthPerceived importance of taking asthma medication as prescribed.
Change in asthma controlbaseline, 1 month, 3 monthSelf-reported asthma control (symptom prevalence, health care utilization)
Change in asthma knowledgebaseline, 1 month, 3 monthKnowledge of asthma and asthma medications
Change in asthma anxietybaseline, 1 month, 3 monthFeelings and anxiety associated with living with asthma.
Change in asthma self-efficacy and attitudebaseline, 1 month, 3 monthSelf-report of self-efficacy to manage asthma effectively; attitude towards asthma and asthma management.
Change in barriers to taking medicationbaseline, 1 month, 3 monthsSelf-report of barriers to taking medication. At baseline and 3 months, daily barriers to taking medications as reported in daily diary.
Change in asthma medication confidenceBaseline, 1 month, 3 monthConfidence in ability to take asthma medications as prescribed.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026